Scancell Holdings plc (SCNLF)
USD 0.18
(0.0%)
USD 0.18
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 27.08 Million GBP | -25.81% |
| 2023 | 36.5 Million GBP | 78.84% |
| 2022 | 20.41 Million GBP | -30.98% |
| 2021 | 29.57 Million GBP | 2427.61% |
| 2020 | 1.17 Million GBP | -2.94% |
| 2019 | 1.2 Million GBP | 73.17% |
| 2018 | 696.09 Thousand GBP | 30.87% |
| 2017 | 531.87 Thousand GBP | -7.6% |
| 2016 | 575.65 Thousand GBP | -4.68% |
| 2015 | 603.91 Thousand GBP | 12.34% |
| 2014 | 537.59 Thousand GBP | 70.6% |
| 2013 | 315.11 Thousand GBP | 10.81% |
| 2012 | 284.38 Thousand GBP | 133.1% |
| 2011 | 122 Thousand GBP | -73.01% |
| 2010 | 452 Thousand GBP | 170.66% |
| 2009 | 167 Thousand GBP | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 30.61 Million GBP | 0.0% |
| 2024 Q4 | 27.08 Million GBP | 0.0% |
| 2024 Q1 | 30.61 Million GBP | -16.13% |
| 2023 Q4 | 36.5 Million GBP | 0.0% |
| 2023 FY | 36.5 Million GBP | 78.84% |
| 2023 Q3 | 36.5 Million GBP | 58.79% |
| 2023 Q1 | 22.98 Million GBP | 12.63% |
| 2023 Q2 | 22.98 Million GBP | 0.0% |
| 2022 Q3 | 33.71 Million GBP | 53.17% |
| 2022 FY | 20.41 Million GBP | -30.98% |
| 2022 Q2 | 22 Million GBP | 0.0% |
| 2022 Q1 | 22 Million GBP | -25.58% |
| 2022 Q4 | 20.41 Million GBP | -39.45% |
| 2021 Q4 | 29.57 Million GBP | 0.0% |
| 2021 FY | 29.57 Million GBP | 2427.61% |
| 2021 Q3 | 29.57 Million GBP | 315.53% |
| 2021 Q2 | 7.11 Million GBP | 0.0% |
| 2021 Q1 | 7.11 Million GBP | 508.29% |
| 2020 Q4 | 1.17 Million GBP | 0.0% |
| 2020 Q1 | 778.29 Thousand GBP | -35.43% |
| 2020 FY | 1.17 Million GBP | -2.94% |
| 2020 Q2 | 778.29 Thousand GBP | 0.0% |
| 2020 Q3 | 1.17 Million GBP | 50.33% |
| 2019 Q3 | 1.2 Million GBP | 160.22% |
| 2019 Q4 | 1.2 Million GBP | 0.03% |
| 2019 Q1 | 463.06 Thousand GBP | -33.48% |
| 2019 Q2 | 463.06 Thousand GBP | 0.0% |
| 2019 FY | 1.2 Million GBP | 73.17% |
| 2018 Q2 | 471.21 Thousand GBP | 0.0% |
| 2018 Q1 | 471.21 Thousand GBP | -11.41% |
| 2018 FY | 696.09 Thousand GBP | 30.87% |
| 2018 Q4 | 696.09 Thousand GBP | 0.0% |
| 2018 Q3 | 696.09 Thousand GBP | 47.72% |
| 2017 Q1 | 579.91 Thousand GBP | 0.74% |
| 2017 Q4 | 531.87 Thousand GBP | 0.0% |
| 2017 Q2 | 579.91 Thousand GBP | 0.0% |
| 2017 FY | 531.87 Thousand GBP | -7.6% |
| 2017 Q3 | 531.87 Thousand GBP | -8.28% |
| 2016 Q1 | 389.1 Thousand GBP | -35.57% |
| 2016 FY | 575.65 Thousand GBP | -4.68% |
| 2016 Q4 | 575.65 Thousand GBP | 0.0% |
| 2016 Q3 | 575.65 Thousand GBP | 47.94% |
| 2016 Q2 | 389.1 Thousand GBP | 0.0% |
| 2015 Q4 | 603.91 Thousand GBP | 0.0% |
| 2015 FY | 603.91 Thousand GBP | 12.34% |
| 2015 Q3 | 603.91 Thousand GBP | 18.63% |
| 2015 Q2 | 509.06 Thousand GBP | 0.0% |
| 2015 Q1 | 509.06 Thousand GBP | -5.31% |
| 2014 Q3 | 537.59 Thousand GBP | 24.88% |
| 2014 Q2 | 430.49 Thousand GBP | 0.0% |
| 2014 Q1 | 430.49 Thousand GBP | 36.62% |
| 2014 FY | 537.59 Thousand GBP | 70.6% |
| 2014 Q4 | 537.59 Thousand GBP | 0.0% |
| 2013 Q4 | 315.11 Thousand GBP | 0.0% |
| 2013 FY | 315.11 Thousand GBP | 10.81% |
| 2013 Q2 | 264.26 Thousand GBP | 0.0% |
| 2013 Q3 | 315.11 Thousand GBP | 19.24% |
| 2012 Q2 | 304 Thousand GBP | 0.0% |
| 2012 FY | 284.38 Thousand GBP | 133.1% |
| 2012 Q4 | 284.38 Thousand GBP | 0.0% |
| 2011 Q4 | 122 Thousand GBP | 0.0% |
| 2011 FY | 122 Thousand GBP | -73.01% |
| 2011 Q2 | 171 Thousand GBP | 0.0% |
| 2010 FY | 452 Thousand GBP | 170.66% |
| 2009 FY | 167 Thousand GBP | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 49.196% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -182.623% |
| SQZ Biotechnologies Company | 50.03 Million USD | 45.88% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 62.632% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 54.111% |
| Mesoblast Limited | 188.44 Million USD | 85.629% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -603.143% |
| Genus plc | 485 Million USD | 94.416% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -363.508% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -976.211% |
| Marizyme, Inc. | 26.67 Million USD | -1.519% |
| ContraFect Corporation | 32.53 Million USD | 16.753% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -612.658% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -1266.824% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -607.51% |
| Intellipharmaceutics International Inc. | 12 Million USD | -125.51% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -129.925% |
| MultiCell Technologies, Inc. | 1617.67 USD | -1673974.44% |
| Accustem Sciences Inc. | 1.07 Million USD | -2409.268% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 65.019% |
| EV Biologics, Inc. | 2.11 Million USD | -1180.384% |
| Q BioMed Inc. | 8.13 Million USD | -232.979% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 67.347% |
| Neon Bloom, Inc. | 1.22 Million USD | -2108.507% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -426.25% |
| Biomind Labs Inc. | 1.49 Million USD | -1707.072% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 88.905% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -47.152% |
| Skye Bioscience, Inc. | 14.07 Million USD | -92.443% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -1247.226% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -18958.376% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -186.089% |
| IMV Inc. | 37.93 Million USD | 28.608% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -13365.363% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -371.316% |
| GB Sciences, Inc. | 5.41 Million USD | -399.875% |
| Alpha Cognition Inc. | 7.16 Million USD | -277.974% |
| HST Global, Inc. | 593.59 Thousand USD | -4462.217% |
| CSL Limited | 18.62 Billion USD | 99.855% |
| Halberd Corporation | 728.71 Thousand USD | -3616.247% |
| Enzolytics Inc. | 365.26 Million USD | 92.586% |
| Resverlogix Corp. | 67.39 Million USD | 59.818% |
| Affymax, Inc. | 8.87 Million USD | -205.276% |
| SYBLEU INC | 681.41 Thousand USD | -3874.242% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -3128.803% |
| argenx SE | 444.95 Million USD | 93.914% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 63.853% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -1479.988% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -127.512% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -638.876% |
| AVAX Technologies, Inc. | 3.99 Million USD | -578.085% |
| Zenith Capital Corp. | 27.56 Thousand USD | -98129.896% |
| Genscript Biotech Corporation | 1.32 Billion USD | 97.957% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -11247.39% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -625.195% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -3877.622% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 77.19% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -199.496% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -40362.281% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -1788.677% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 46.122% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -898.694% |
| BioStem Technologies, Inc. | 15.9 Million USD | -70.271% |
| ONE Bio Corp. | 27.49 Million USD | 1.509% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -5727.643% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -98616.874% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -2050.663% |
| Agentix Corp. | 2.51 Million USD | -978.686% |
| LadRx Corporation | 2.2 Million USD | -1130.659% |
| Cell Source, Inc. | 15.8 Million USD | -71.326% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -60489.314% |
| Regen BioPharma, Inc. | 5.45 Million USD | -396.206% |
| Regen BioPharma, Inc. | 5.45 Million USD | -396.206% |
| NovAccess Global Inc. | 7.86 Million USD | -244.51% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -9.436% |
| Itoco Inc. | 1.65 Million USD | -1538.144% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -1220.017% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -347.694% |
| Kadimastem Ltd | 3.5 Million USD | -672.668% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -6323.875% |
| CytoDyn Inc. | 127.89 Million USD | 78.825% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -64688.631% |
| Mobile Lads Corp. | 1.31 Million USD | -1961.748% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -1628.894% |
| Qrons Inc. | 1.48 Million USD | -1719.088% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -145.181% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -3248.319% |
| Rebus Holdings, Inc. | 5.24 Million USD | -416.616% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -343.812% |
| International Stem Cell Corporation | 5.27 Million USD | -413.189% |
| Bioxytran, Inc. | 3.24 Million USD | -733.39% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -4227.359% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -486.534% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 33.942% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -21.63% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -1237.078% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -394.359% |
| Neutra Corp. | 973.52 Thousand USD | -2681.735% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 6.666% |
| PureTech Health plc | 125.58 Million USD | 78.436% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -620.79% |
| IXICO plc | 1.9 Million USD | -1325.097% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -31.916% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 73.79% |
| CSL Limited | 18.62 Billion USD | 99.855% |
| Cellectis S.A. | 249.36 Million USD | 89.14% |